BRNS – barinthus biotherapeutics plc - american depositary shares (US:NASDAQ)
Stock Stats
News
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-CMA, HFWA, BRNS, and FITB
Barinthus Biotherapeutics (NASDAQ:BRNS) had its price target raised by analysts at HC Wainwright from $3.00 to $4.00. They now have a "buy" rating on the stock.
Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments
ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders
Form 10-Q Barinthus Biotherapeutic For: Sep 30
Form 8-K Barinthus Biotherapeutic For: Nov 07
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.